Lexanox

Quick links to important sections

Lexanox

Method of action: Stomatological Preparations

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexanox

Quick Facts

Property Description
Active ingredient Amlexanox (INN)
Form Topical Paste (Oral Paste)
Pharmacological class Anti-inflammatory agent and Immunomodulator
Common use Provides symptomatic relief for localized oral inflammation
Origin Synthetic organic compound

What is Lexanox and What is its Active Ingredient?

Lexanox is the trade name for a medicinal product whose active component is Amlexanox (International Nonproprietary Name, or INN). This drug is a synthetic organic compound typically formulated as a Topical Paste for localized application to the oral mucosa.

The foundation of this medication is Amlexanox, a unique chemical entity derived from a benzopyrano-bipyridine carboxylic acid structure. The product is generally designed as a single-agent product but may also be found in certain combination product variations. Amlexanox's structure confirms its classification as a non-steroidal compound. Its primary action involves inhibiting the release of allergic mediators, which helps address inflammatory symptoms by regulating the body's chemical response.

What Type of Medicine is Lexanox? (Pharmacological Class)

Lexanox is classified pharmacologically as both an anti-inflammatory agent and an immunomodulator, signifying its function in regulating the body's local immune response and mitigating inflammation.

This classification reflects the fundamental action of Amlexanox as an inhibitor of inflammatory mediators release, which intervenes in the chemical signaling of certain immune cells. It regulates the production and discharge of substances such as histamine and leukotrienes that trigger swelling, redness, and pain. Amlexanox acts to suppress the release of histamine from mast cells and the production of leukotriene D4, establishing its utility in topical inflammatory management.

What is the General Purpose of Lexanox Paste?

The general purpose of the Lexanox Oral Paste is to use its local anti-inflammatory action to provide symptomatic relief and support the natural healing process for localized inflammatory conditions in the mouth.

The Topical Paste formulation, utilizing a mucoadhesive vehicle, is engineered to ensure that the active ingredient remains in prolonged contact with the affected tissue, maximizing its therapeutic benefit. By regulating the inflammatory cascade directly at the site of application, the product aims to reduce the characteristic discomfort, swelling, and redness that are typically experienced with common oral mucosal irritations, thereby contributing to tissue recovery.

What side effects are possible with Lexanox?

Possible Side Effects and Safety Information

The safety characteristics of Lexanox (Amlexanox Oral Paste) are formally documented in regulatory labeling, with adverse reactions classified primarily by frequency and the body system affected. Since the medicine is applied topically, side effects are most often localized to the application area, though systemic effects are documented.

Officially Documented Adverse Reactions

Adverse reactions are grouped according to standard regulatory classification. Reactions reported by 1% to 2% of patients in clinical studies are often categorized as Common.

Classification Examples of Documented Reactions
Common Pain, stinging, or burning at the site of application.
Uncommon Nausea, diarrhea, oral mucositis, dry lips, contact dermatitis, new aphthous ulcers.

Systemic and Serious Safety Considerations

The labeling includes reactions across several System-Organ Classes, including Gastrointestinal disorders and Immune System Disorders. A key safety element is the potential for Hypersensitivity, which is classified as uncommon but includes the serious possibility of angioedema (swelling beneath the skin or mucosa).

Use is formally contraindicated in patients with a known hypersensitivity to Amlexanox or any other ingredient in the paste formulation. No specific drug interaction studies have been formally performed for this topical product.

Population-Specific Safety Notes

Specific safety statements are included for certain patient groups:

  • Pediatric Use: The safety and effectiveness of the paste have not been established in pediatric patients.
  • Geriatric Use: Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently.
  • Pregnancy and Lactation: The medication is classified as Pregnancy Category B and caution is advised for nursing mothers.

Overdose and Emergency Response

Lexanox Overdose and When to Seek Help

Overdose with Amlexanox Topical Paste (Lexanox) is generally considered in the context of accidental oral ingestion of the entire contents of a tube.

Category Official Regulatory Statement
Documented Manifestations Non-specific gastrointestinal distress and local irritation are the primary potential outcomes reported following accidental ingestion.
Severity and Outcomes No specific severe or life-threatening systemic outcomes are formally documented, due to the active ingredient's low concentration and limited systemic exposure.
Antidote and Treatment No specific antidote is known. Management must be focused on providing symptomatic and supportive treatment. Hospital monitoring may be required for observation following ingestion.

Required Emergency Action

Urgent medical attention is required for any suspected or known overdose scenario, regardless of the expected low toxicity. Regulatory labeling explicitly mandates that patients seek immediate medical attention and contact a Poison Control Center immediately for specialized guidance. This ensures proper assessment and monitoring of vital signs can take place. The overdose profile is thus defined by the low expected clinical risk, which is offset by the clear procedural requirement for professional medical assessment.

Therapeutic Uses of Lexanox

What Lexanox Treats: Main Uses and Benefits

Lexanox is considered relevant for managing conditions characterized by periods of heightened symptoms in the oral cavity. The medication is commonly used for the treatment of aphthous ulcers (canker sores), which are common manifestations presenting with localized discomfort. It is applied across domains where additional symptomatic support for conditions like Recurrent Aphthous Ulcers and other local oral lesions may be needed.

A key benefit of this medication may be its ability to assist in addressing symptom clusters that may become intense or disruptive, such as acute local pain and associated localized inflammation. It supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable. This is commonly used when symptoms interfere with routine activities, assisting with functional strain during symptomatic phases.

“It is commonly used across conditions presenting with acute episodes, relevant for easing the pain and inflammation accompanying recurrent oral lesions.”


Quick Facts: Relief for Aphthous Ulcers

Domain Focus Benefit
Symptom Axes Acute local pain and inflammation Supports general well-being during symptomatic phases
Condition Frame Recurrent Aphthous Ulcers (Canker Sores) Supports the patient during difficult episodes by easing distress
Use Context Acute symptom flare-ups Assists with maintaining functional stability

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lexanox — Official Regulatory Information


Eligibility Scope

Classification Population Status Restrictions/Limitation
Allowed Use Adults (18+) Established Must be immunocompetent
Allowed Use Adolescents (12+) Established Use is not indicated below age 12
Contraindicated Hypersensitivity Prohibited Allergy to Amlexanox or formulation ingredients
Contraindicated Abnormal Immune System Not Indicated Safety and effectiveness not assessed

Condition-Specific Eligibility

Classification Population/Condition Regulatory Guidance
Conditional Use Renal/Hepatic Impairment Caution should be exercised; specific studies are lacking
Conditional Use Pregnancy Restricted (EU: Not recommended; FDA: Category B, use only if clearly needed)
Conditional Use Lactation (Nursing) Restricted (EU: Not recommended; FDA: Caution should be exercised)
Data Insufficient Geriatric Patients (65+) Data not sufficient to determine differential response

Connection to the Overall Eligibility Profile

Official regulatory documents define the eligible user base for Lexanox by explicitly contraindicating use due to known hypersensitivity and age below 12 years, and by noting use is not indicated for immunocompromised individuals. Furthermore, regulatory agencies impose restrictions and require caution for populations lacking sufficient clinical data, specifically patients with hepatic or renal impairment, older adults, and pregnant or nursing women. This structure formally demarcates the boundaries of established and restricted use according to regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Lexanox (Amlexanox oral paste) is characterized by a lack of documented systemic drug interactions. This is consistent with its topical formulation and very low systemic exposure. No specific medicinal products are formally designated as contraindicated for co-administration due to interaction risk.

Pharmacokinetic Interaction Risk

Regulatory assessments indicate that Amlexanox has a minor effect on various Cytochrome P450 (CYP450) isozymes in vitro, showing less than a 10% change in activity. Based on this minimal activity, the active ingredient is considered unlikely to have a significant metabolic effect on co-administered drugs metabolized by the CYP450 pathway. Furthermore, some official summaries state that no dedicated systemic drug-drug interaction studies have been performed to evaluate potential pharmacokinetic or pharmacodynamic interactions.

Substance and Population Considerations

No systemic interactions are documented with food, herbal products, or supplements. However, alcohol and nicotine are noted to potentially cause local irritation to the oral lesions being treated, which is a condition-based interaction constraint. Regarding specific patient populations, caution is noted in patients with hepatic or renal impairment due to the absence of specific data concerning altered clearance or interaction risks in these groups.

Mechanism of Action

Mechanism of Bone Resorption Modulation

Lexanox functions as a competitive inhibitor of the cysteine protease cathepsin K. This enzyme exhibits high selectivity and is principally expressed within osteoclasts, the specialized cells responsible for bone resorption. Cathepsin K is released into the resorption lacuna, an acidic microenvironment formed between the osteoclast and the bone surface. Here, the enzyme cleaves type I collagen, elastin, and other non-collagenous proteins, initiating the degradation of the organic bone matrix. By occupying the active site of cathepsin K, Lexanox prevents this degradation process. This molecular action modulates osteoclast function, consequently reducing the overall rate of bone resorption and limiting the mobilization of bone minerals.

Dosage and Administration Information

Administration Guidelines for Lexanox Oral Paste

Lexanox (Amlexanox Oral Paste 5%) is described by instructions for use focusing strictly on the topical application protocol. These instructions establish the standardized method for administering the medicine, including dose, frequency, and preparatory steps.


Feature Administration Guidelines
Route of administration Topical application to the oral mucosa.
Dosing schedule Apply approximately 0.5 cm (or 1/4 inch) of the paste to each affected ulcer.
Frequency and timing Four times daily (QID), preferably following oral hygiene after breakfast, lunch, dinner, and at bedtime.
Preparation requirements The ulcer should be gently dried with a clean cloth before application. The fingertip may be moistened before squeezing the paste.
Age-group rules Pediatric Use: Safety and effectiveness have not been established.
Missed-dose rules If a dose is missed, apply it as soon as possible, but skip the dose if it is almost time for the next scheduled dose (do not double dose).
Special procedural conditions The paste is for oral cavity use only. Treatment should continue until the ulcer heals, up to a maximum duration of 10 days; consultation is required if the ulcer persists beyond this limit.

Procedural Structure

Step sequence:

  • Dry the surface of the oral ulcer gently with a clean cloth.
  • Squeeze the measured amount of paste (0.5 cm) onto a fingertip.
  • Gently dab the paste onto the ulcer until it is covered, without rubbing it in.
  • Apply the paste four times daily according to the established post-meal/bedtime schedule.
  • Discontinue use once the ulcer has healed, or consult a health professional if the ulcer persists beyond the defined maximum treatment duration.

Connection to the overall use protocol: The instructions define a standardized protocol where the medicine is applied locally, in a fixed quantity, at specific times relative to daily activities. This structure establishes a clear framework for how the topical medicine is to be administered over a short-term, finite course, ensuring procedural consistency across users.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lexanox

Evidence for use in Recurrent Aphthous Ulcers (Canker Sores)

The core clinical evaluation for Lexanox paste was evaluated in short-term, randomized controlled trials (RCTs). These studies are designed using controlled methods to evaluate clinical outcomes in patients experiencing minor aphthous ulcers, which are conditions characterized by fluctuating or episodic manifestations. Researchers monitored measurements of lesion resolution and measurements of the cessation of pain-related physical discomfort. Findings describe patterns observed in the studies where research explored whether the measurements of lesion resolution or pain cessation differed between the groups receiving the active ingredient and the groups using the inactive paste (vehicle). This evidence contributes to understanding symptom patterns and the short-term changes observed.

How Lexanox Studies Compare to Inactive Pastes

Research was designed to compare the results of the paste containing the active ingredient (Amlexanox) against a vehicle (the inactive base paste). This approach was used to examine the specific contribution of the active ingredient relative to the protection offered by the inactive paste alone. Findings described patterns where the groups using the active ingredient differed from the vehicle-alone group in measurements of healing rate. However, findings were mixed, as some studies also reported that the inactive vehicle alone was also associated with measured changes in patient symptoms.

Duration of Evidence: Short-Term vs. Long-Term Follow-up and Research Gaps

The research base primarily focuses on the acute phase of treatment, evaluating patients over a limited follow-up duration, typically three to seven days. While some trials tracked patients up to 60 days to see if the frequency of ulcer recurrence changed, long-term effects are not fully established. Research has not yet established whether the application of the paste during an acute flare-up is associated with changes in the cycle or frequency of future episodes. Furthermore, evidence is limited for severe (major) aphthous ulcers and in specific patient groups, such as children under 12 years of age or individuals with systemic health conditions. Comparative evidence for how the paste performs against all other available treatment types is lacking. Research does not provide certainty about individual outcomes, as findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Lexanox (FAQ)


Q: What happens if I forget to take Lexanox one time?

According to the official product information, if an application is missed, it can be applied as soon as it is remembered. However, it is generally recommended to skip the dose if the next scheduled application time is near and continue with the regular schedule. Official guidance indicates that a double amount should not be used to compensate for a missed dose.


Q: Is it common to feel a little dizzy when first starting Lexanox?

Official information does not list dizziness among the most common adverse reactions reported in clinical studies for the topical paste. However, severe dizziness is noted as a rare symptom of a serious allergic reaction, which is classified as an uncommon event. Consultation with a healthcare professional is generally recommended immediately if severe dizziness or any signs of a serious reaction occur.


Q: Can Lexanox be used by people who have [specific common condition, e.g., high blood pressure]?

The official regulatory documents advise caution for patients with kidney (renal) or liver (hepatic) impairment because specific studies in these groups are lacking. Official guidance is limited to statements concerning hepatic or renal impairment and does not offer specific guidance concerning other common chronic conditions, such as high blood pressure.


Q: Can Lexanox be taken with alcohol (informational query)?

Regulatory documents note that no systemic drug interaction is formally documented with alcohol, which is consistent with the medicine's low systemic absorption. However, official information does note that alcohol may potentially cause local irritation to the oral lesions being treated.


Q: If I have a history of [specific mental health condition], is Lexanox still an option?

The official regulatory profile does not list specific restrictions or cautions related to a history of mental health conditions. Contraindications are limited to hypersensitivity to the ingredients, and use is not indicated for those with an abnormal immune system.


Q: What happens if Lexanox is stopped suddenly?

The official instructions define a maximum duration of use (7 to 10 days) and describe stopping use once the ulcer has healed. Regulatory documents do not specifically address or describe any withdrawal or rebound effects that might occur from discontinuing the paste suddenly outside of this established protocol.


Q: Can taking Lexanox affect my ability to drive or operate machinery?

Official regulatory documents do not contain a direct statement regarding the effect of Lexanox on the ability to drive or use machinery. The medicine is applied topically, resulting in low amounts of the active ingredient reaching the bloodstream, and common side effects are mainly localized to the area of application.


Q: Does Lexanox interact with vitamins or herbal supplements?

Official regulatory assessments state that no systemic interactions are documented with food, herbal products, or vitamin supplements. This is based on the topical nature of the medicine and the finding that the active ingredient is considered unlikely to have a significant metabolic effect on co-administered substances.


Q: How quickly should I expect to notice any effects from Lexanox?

Clinical studies supporting the use of Lexanox measured outcomes such as healing rate and the cessation of pain. Findings indicate that research outcomes, such as pain relief, have been observed in studies within the short-term treatment course of a few days.


Q: Does Lexanox cause changes in appetite or weight?

Official regulatory documents and adverse event listings for the topical paste formulation do not list appetite change or weight change among the documented adverse reactions reported in clinical studies.


Q: Are the side effects of Lexanox generally short-lived?

The most common documented reactions, such as pain, stinging, or burning at the site of application, are formally described as transient (short-lived) in regulatory labeling. Other documented systemic reactions are classified as uncommon.


Q: What if Lexanox does not seem to be working for me after a few weeks?

The official instructions define the maximum recommended treatment duration as 7 to 10 days, depending on the source. If the ulcer persists or has not significantly healed beyond this maximum duration, official guidance is to seek consultation with a health professional.


Q: How does Lexanox interact with common over-the-counter pain relievers?

The active ingredient in Lexanox is considered unlikely to have a significant metabolic effect on other medicines, including over-the-counter pain relievers, due to its low systemic absorption and minimal effect on the body's major enzyme system (CYP450). No specific systemic drug interaction studies have been formally performed.


Q: Is there a generic version of Lexanox available?

Lexanox contains the active ingredient Amlexanox and has been marketed under different brand names globally. The brand name for Amlexanox oral paste in the US (Aphthasol) has been discontinued, though generic forms of the active ingredient may be available in some global markets.


Q: Why does Lexanox sometimes cause stomach upset?

Gastrointestinal reactions such as nausea and diarrhea are listed as uncommon side effects. Regulatory documents indicate that most of the systemic absorption occurs via the gastrointestinal tract after the paste is swallowed, which may lead to these systemic effects.


Q: Is it possible to take Lexanox with other prescription medications for [broad health area]?

The official regulatory profile for this topical medicine is characterized by a lack of documented systemic drug interactions. This is due to its topical formulation and very low systemic exposure, meaning it is considered unlikely to significantly affect the metabolism of other prescription drugs.


Q: How long does Lexanox stay in my system after the last use?

After the swallowed portion of the paste is absorbed by the body, the active ingredient is processed and eliminated relatively quickly. The elimination half-life has been measured in healthy individuals as approximately 3.5 hours.


Q: What clinical trials support the use of Lexanox?

The core clinical evaluation for Lexanox paste was based on short-term randomized controlled trials (RCTs). These studies focused on patients with minor aphthous ulcers and provided evidence to support the understanding of short-term healing patterns and pain cessation.


Q: Why is a specific monitoring (e.g., blood test) sometimes required when using Lexanox?

While no specific standard monitoring is generally required, regulatory documents advise caution for patients with existing kidney or liver impairment. This may be a reason for a healthcare professional to require additional monitoring, such as blood tests, due to a lack of specific data on the medicine’s clearance in these patient groups.


Q: Is Lexanox known to affect sleep patterns?

Official regulatory documents on the topical paste formulation do not list sleep disturbances or insomnia among the documented adverse reactions reported in clinical studies.


Q: What is the role of the [target enzyme/receptor name] in how Lexanox works?

The active ingredient in Lexanox functions by targeting a specific enzyme. It is described as an inhibitor of the cysteine protease cathepsin K, which is an enzyme principally found in specialized cells called osteoclasts.


Q: Can Lexanox affect birth control pills?

The active ingredient is considered unlikely to have a significant metabolic effect on co-administered drugs, including hormonal contraceptives. This is supported by the medicine’s low systemic exposure and minimal effect on the body’s major enzyme system, the CYP450 isozymes.


Q: What is the experience of people using Lexanox for a year or more?

Studies supporting the official use of Lexanox paste primarily focus on the acute phase of treatment with a limited follow-up duration. The long-term effects of applying the paste during acute flares, including whether it is associated with changes in the frequency of future episodes, are not fully established by current research.


Q: Is it normal to have a small rash when first taking Lexanox?

Official documents list contact dermatitis and a rash as documented adverse reactions to the paste. A rash, while possible, is classified as a potential adverse reaction. It is generally advised that a healthcare professional be consulted if a rash develops.


Q: How often do people need to adjust their Lexanox plan?

Lexanox is designed for a short-term, finite course, with official instructions defining a maximum duration of 7 to 10 days. The plan is adjusted in the event the ulcer persists beyond this limit, which typically involves consultation with a health professional.


Q: Is Lexanox safe to use in combination with common anti-anxiety medications?

The official regulatory profile is characterized by a lack of documented systemic drug interactions. Because the product is topical with very low systemic exposure, the active ingredient is considered unlikely to significantly affect the metabolism of co-administered drugs like common anti-anxiety medications.


Q: Does the time of day matter when taking Lexanox?

The official instructions advise that the medicine be applied four times daily (QID), specifically following oral hygiene after breakfast, lunch, dinner, and at bedtime. This specific schedule is described as a preference to maximize the time the paste stays in contact with the ulcer.

How should Lexanox be stored and disposed of?

Storage and Disposal Conditions for Amlexanox Oral Paste (Lexanox)

Amlexanox oral paste, 5%, must be stored at Controlled Room Temperature, which is defined by official regulatory bodies as a temperature between 15 C and 30 C (59 F and 86 F). The medication must be kept out of the reach of children as a standard safety measure.

Container Requirements

The product should not be used if the outer packaging is opened or if the blister containing the medicine is torn or broken. Maintaining the integrity of the original container is essential for product quality.

Disposal

To dispose of unused or expired Lexanox, individuals must follow official governmental guidelines. Consumers should learn how to safely dispose of unused or expired drugs through authorized collection sites or specific local instructions for safe household disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lexanox found in:

A-Z Index: